BIOMAT Database Logo BIOMAT Database Logo

Sodium valproate in Cushing's disease. 1984

F Cavagnini, and C Invitti, and E E Polli

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

F Cavagnini, and C Invitti, and E E Polli
Sodium valproate and metyrapone for pituitary-dependent Cushing's disease.
September 1984, Lancet (London, England),
F Cavagnini, and C Invitti, and E E Polli
Cyclical Cushing's disease and its successful control under sodium valproate.
December 1990, Journal of endocrinological investigation,
F Cavagnini, and C Invitti, and E E Polli
Failure of long-term therapy with sodium valproate in Cushing's disease.
January 1997, Journal of endocrinological investigation,
F Cavagnini, and C Invitti, and E E Polli
The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
August 1988, Klinische Wochenschrift,
F Cavagnini, and C Invitti, and E E Polli
[Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine].
January 1991, Revista clinica espanola,
F Cavagnini, and C Invitti, and E E Polli
Sodium valproate and heterogeneity of pituitary dependent Cushing's syndrome.
May 1982, Lancet (London, England),
F Cavagnini, and C Invitti, and E E Polli
Fever of unexplained origin, biochemical Cushing's disease and cerebral dysrhythmia corrected by valproate sodium.
January 1985, Canadian Medical Association journal,
F Cavagnini, and C Invitti, and E E Polli
Valproate in Cushing's syndrome.
January 1982, Lancet (London, England),
F Cavagnini, and C Invitti, and E E Polli
Sodium valproate in Huntington's disease.
March 1978, The American journal of psychiatry,
F Cavagnini, and C Invitti, and E E Polli
Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease.
October 1983, Acta endocrinologica,
Copied contents to your clipboard!